行情

INSM

INSM

Insmed
NASDAQ

实时行情|Nasdaq Last Sale

19.58
+0.05
+0.26%
盘后: 19.58 0 0.00% 17:01 09/20 EDT
开盘
19.49
昨收
19.53
最高
19.66
最低
19.21
成交量
363.52万
成交额
--
52周最高
33.13
52周最低
11.31
市值
17.47亿
市盈率(TTM)
-4.7806
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INSM 新闻

  • Insmed (NASDAQ:INSM) Has Debt But No Earnings; Should You Worry?
  • Simply Wall St..4天前
  • Insmed (INSM) Investor Presentation - Slideshow
  • Seeking Alpha - Article.6天前
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire.09/05 21:05
  • Benzinga's Top Upgrades, Downgrades For September 3, 2019
  • Benzinga.09/03 13:42

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

INSM 简况

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
展开

Webull提供Insmed Incorporated的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。